Changes in Serologic Markers of Hepatitis B Following Autologous Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 4, 2007, Pages 463-468

  Uhm, Ji Eun ^a   Kim, Kihyun ^a   Lim, Tae Kyu ^a   Park, Byeong Bae ^a   Park, Sarah ^a   Hong, Yong Sang ^a   Lee, Sang Cheol ^a   Hwang, In Gyu ^a   Koh, Kwang Cheol ^a   Lee, Mark H ^b   Ahn, Jin Seok ^a   Kim, Won Seog ^a   Jung, Chul Won ^a   Kang, Won Ki ^a  

^a Samsung Medical Center   (South Korea)

^b Konkuk University Hospital   (South Korea)

Author keywords

Autologous hematopoietic stem cell transplantation; Hepatitis; Hepatitis B virus

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MELPHALAN; THALIDOMIDE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CONFIDENCE INTERVAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE MYELOMA; PATIENT INFORMATION; RETROSPECTIVE STUDY; SEROCONVERSION; SEROLOGY; SOLID TUMOR; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; ENDEMIC DISEASES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOCOMPROMISED HOST; KOREA; LAMIVUDINE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEROLOGIC TESTS; TRANSPLANTATION, AUTOLOGOUS;

EID: 33947212507     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.11.019     Document Type: Article

References (27)

1. Strasser S.I., and McDonald G.B. Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management. Blood 93 (1999) 1127-1136
2. Ohnishi M., Kanda Y., Takeuchi T., et al. Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients. Transplantation 73 (2002) 812-815
3. Senecal D., Pichon E., Dubois F., Delain M., Linassier C., and Colombat P. Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus. Bone Marrow Transplant 24 (1999) 1243-1244
4. Hui C.K., Sun J., Au W.Y., et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 42 (2005) 813-819
5. Goyama S., Kanda Y., Nannya Y., et al. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation. Leuk Lymphoma 43 (2002) 2159-2163
6. Ma S.Y., Lau G.K., Cheng V.C., and Liang R. Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation. Leuk Lymphoma 44 (2003) 1281-1285
7. Lee D.-H., Kim J.-H., Nam J.-J., Kim H.-R., and Shin H.-R. Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci 17 (2002) 457-462
8. Knoll A., Boehm S., Hahn J., Holler E., and Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 33 (2004) 925-929
9. Kempinska A., Kwak E.J., and Angel J.B. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis 41 (2005) 1277-1282
10. Dhedin N., Douvin C., Kuentz M., et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 66 (1998) 616-619
11. Onozawa M., Hashino S., Izumiyama K., et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 79 (2005) 616-619
12. Niesters H.G., Krajden M., Cork L., et al. A multicenter study evaluation of the Digene Hybrid Capture II signal amplification technique for detection of hepatitis B virus DNA in serum samples and testing of EUROHEP standards. J Clin Microbiol 38 (2000) 2150-2155
13. Hsiao L.T., Chiou T.J., Liu J.H., et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 12 (2006) 84-94
14. Chen P.M., Liu J.H., Fan F.S., et al. Liver disease after bone marrow transplantation-the Taiwan experience. Transplantation 59 (1995) 1139-1143
15. Lau G.K., Leung Y.H., Fong D.Y., et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 99 (2002) 2324-2330
16. Lai C.L., Chien R.N., Leung N.W., et al., Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339 (1998) 61-68
17. Hussain M., and Lok A.S. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. J Viral Hepat 6 (1999) 183-194
18. Leung N. Nucleoside analogues in the treatment of chronic hepatitis B. J Gastroenterol Hepatol 15 suppl (2000) E53-E60
19. Liaw Y.F., Leung N.W., Chang T.T., et al., Asia Hepatitis Lamivudine Study Group. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119 (2000) 172-180
20. Silvestri F., Sperotto A., Ermacora A., Fanin R., Damiani D., and Baccarani M. Lamivudine for the prevention of hepatitis B virus reactivation during autologous stem cell transplantation. A case report. Haematologica 85 (2000) 327-329
21. Uchida N., Gondo H., Himeji D., Kaji Y., Sata M., and Niho Y. Lamivudine therapy for a hepatitis B surface antigen (HBsAg)-positive leukemia patient receiving myeloablative chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 26 (2000) 1243-1245
22. Endo T., Sakai T., Fujimoto K., et al. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 27 (2001) 433-436
23. Chan T.M., Fang G.X., Tang C.S., Cheng I.K., Lai K.N., and Ho S.K. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 36 (2002) 1246-1252
24. Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J Antimicrob Chemother 55 (2005) 828-831
25. Nordbo S.A., Skaug K., Holter E., Waage A., and Brinch L. Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation. Eur J Haematol 65 (2000) 86-87
26. Tur-Kaspa R., Shaul Y., Moore D.D., et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 167 (1988) 630-633
27. van Tol M.J., Gerritsen E.J., de Lange G.G., et al. The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation. Blood 87 (1996) 818-826